What is Aytu Biopharma, Inc worth?
With the base-case assumptions below, a discounted cash flow model on Aytu Biopharma, Inc's reported free cash flow gives $4.34 per share. The share price was $2.28 on September 25, 2026, 47% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | -7.5% | 10.0% | $3.20 | +40% |
| Base | -2.5% | 9.0% | $4.34 | +90% |
| Bull | 2.5% | 8.0% | $6.56 | +188% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $5.12 | $5.35 | $5.63 | $5.98 | $6.43 |
| 8.0% | $4.54 | $4.69 | $4.87 | $5.08 | $5.34 |
| 9.0% | $4.12 | $4.22 | $4.34 | $4.48 | $4.64 |
| 10.0% | $3.80 | $3.87 | $3.95 | $4.05 | $4.15 |
| 11.0% | $3.54 | $3.59 | $3.65 | $3.72 | $3.80 |
Where the presets come from
Base: years 1 to 5 grow at Aytu Biopharma, Inc's revenue growth rate over the last 5 fiscal years (-2.6% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions